Floatz logo

Tebotelimab

Cervical Cancer

MacroGenicsmonoclonal_antibodyPhase 1Dormant
D
27/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
14/ 100
Competitive Position
65/ 100

Competitive context

160 Active assets in the Cervical Cancer cohort.

Asset / SponsorPhaseRating
Vinorelbine
UNICANCER
Phase 2BBB
Indocyanine Green
Istanbul University
Phase 4BB
Tisotumab Vedotin
Seagen Inc.
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Uganda Cancer Institute
Phase 3B
Carboplatin
Merck Sharp & Dohme LLC
Phase 3B

View all 50 →

Same molecule, other indications

Tebotelimab is also rated in:

hepatocellular carcinomaDormant
D
Indicative ·
30 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
D
Indicative ·
29 / 100
View asset →
metastatic neoplasmDormant
D
Indicative ·
29 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →